Market capitalization | $1.99b |
Enterprise Value | $1.23b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.51 |
P/S ratio (TTM) P/S ratio | 5.70 |
P/B ratio (TTM) P/B ratio | 2.51 |
Revenue growth (TTM) Revenue growth | 328.73% |
Revenue (TTM) Revenue | $349.64m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
18 Analysts have issued a Beam Therapeutics Inc forecast:
18 Analysts have issued a Beam Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 350 350 |
329%
329%
|
|
Gross Profit | 328 328 |
512%
512%
|
|
EBITDA | -161 -161 |
57%
57%
|
EBIT (Operating Income) EBIT | -183 -183 |
54%
54%
|
Net Profit | -144 -144 |
54%
54%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.
Head office | United States |
CEO | John Evans |
Employees | 436 |
Founded | 2017 |
Website | www.beamtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.